Kurse werden geladen...
Anzeige
Prognose
Für dieses Unternehmen liegen uns keine Analysten-Daten vor.
Scoring-Modelle
Für dieses Unternehmen liegen uns bisher keine Scoring-Modelle vor.
News
Treatment.com AI and Rocket Doctor Applaud US Health Secretary RFK Jr.'s Call for Greater Investment in Telehealth and AI-Driven Diagnostic Tools
VANCOUVER, BC, May 15, 2025 (GLOBE NEWSWIRE) -- Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (“Treatment”) and Rocket Doctor, its wholly owned online care platform, applaud United States Secretary of Health and Human Services, Robert F. Kennedy Jr., for his remarks during the House Appropriations Committee Budget Hearing yesterday, where he championed the potential role of telehealth and artificial intelligence in improving access to care.» Mehr auf globenewswire.com
Rocket Doctor Named Clinical Innovator of the Year at NEXUS 2025
Recognition highlights Rocket Doctor's leadership in advancing physician-led virtual care models across North America Recognition highlights Rocket Doctor's leadership in advancing physician-led virtual care models across North America» Mehr auf globenewswire.com
Treatment.com AI Closes Previously Announced Acquisition of Rocket Doctor Inc.
THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, April 10, 2025 (GLOBE NEWSWIRE) -- Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (“Treatment”) is pleased to announce, further to its news release of February 12, 2025, that it has closed the acquisition of 100% of the issued and outstanding securities of Rocket Doctor Inc. (the “Transaction”) pursuant to the terms and conditions of a Share Purchase Agreement dated February 11, 2025, as amended (the “Definitive Agreement”) with Rocket Doctor Inc. (“Rocket Doctor”) and the common shareholders of Rocket Doctor. Rocket Doctor is a Canadian federally incorporated company with a US Delaware subsidiary, which aims to transform the way healthcare is delivered, through empowering doctors to start their own virtual practices, thereby providing citizens with quick access to high-quality, comprehensive medical care, powered by advanced devices and proprietary technology.» Mehr auf globenewswire.com
Unternehmenszahlen
| (EUR) | Dez. 2024 | |
|---|---|---|
| Umsatz | 0,00 | 100,00% |
| Bruttoeinkommen | 0,00 | 100,00% |
| Nettoeinkommen | −1,51 Mio | 0,43% |
| EBITDA | −1,51 Mio | 158,94% |
Fundamentaldaten
| Metrik | Wert |
|---|---|
Marktkapitalisierung | 17,39 Mio€ |
Anzahl Aktien | 58,00 Mio |
52 Wochen-Hoch/Tief | 0,82€ - 0,0422€ |
| Dividenden | Nein |
Beta | -0,6 |
KGV (PE Ratio) | −2,65 |
KGWV (PEG Ratio) | −0,08 |
KBV (PB Ratio) | 25,27 |
KUV (PS Ratio) | 2.427,72 |
Anzeige
Unternehmensprofil
Treatment.Com International Inc. bietet personalisierte Gesundheitsinformationsdienste in Kanada an. Es entwickelt auch eine mobile Anwendung für die Bewertung von Symptomen der Nutzer, um ihre gesundheitlichen Bedenken, Probleme und laufende Wellness-Management zu behandeln. Das Unternehmen bietet eine digitale Gesundheits-App, ein Bewertungsinstrument, das Einblicke in die Gesundheit bietet. Darüber hinaus bietet das Unternehmen medizinische Ausbildung, medizinische Klinik, und klinische Berater-Lösungen; und bietet Gesundheits-Informations-Ressource. Treatment.Com International Inc. wurde im Jahr 2018 gegründet und hat seinen Hauptsitz in Vancouver, Kanada.
| Name | Treatment.com International Aktie |
| CEO | Dr. Essam Hamza M.D. |
| Sitz | Vancouver, bc Kanada |
| Website | |
| Börsengang | |
| Mitarbeiter | 3 |
Ticker Symbole
| Börse | Symbol |
|---|---|
Pnk | TREIF |
Cnq | TRUE.CN |
Frankfurt | 939.F |
München | 939.MU |
Düsseldorf | 939.DU |
Assets entdecken
Shareholder von Treatment.com International Aktie investieren auch in folgende Assets
